In conclusion, CDKN2A LOF negatively impacts clinical outcomes in advanced NSCLC treated with ICB, doubling rates of disease progression and halving PFS and OS, even in high PD-L1 and high TMB tumors. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.